Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dopamine may unclog lymphatic system in rare heart complication

NCT ID NCT03322345

Terminated Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at whether dopamine can improve lymph flow in people who developed protein-losing enteropathy (PLE) after Fontan surgery for single-ventricle heart disease. PLE is a serious complication where proteins leak into the gut, possibly due to poor lymphatic function. Researchers will track markers of lymph circulation and PLE symptoms in a small group of patients receiving dopamine along with standard treatments during flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dopamine
What this could lead to
If successful, this could clarify whether dopamine improves lymphatic function in Fontan-associated protein-losing enteropathy, potentially pointing toward a new treatment approach.
What could go wrong
This is a very small observational study (only 3 participants) with no control group, so results may not be generalizable. It is exploratory and may not lead to a proven therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATECHOLAMINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital heart disease protein-losing enteropathy univentricular heart

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATECHOLAMINE CONGENITAL HEART DISEASE DOPAMINE LYMPH LYMPHATIC SYSTEM PROTEIN-LOSING ENTEROPATHIES SINGLE-VENTRICLE

Contacts and locations

Locations

  • University of Michigan Health System

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.